G360 2025: The latest in glaucoma devices and pharmaceuticals

News
Video

John Berdahl, MD, overviews the new FYXS Ocular Pressure Adjusting Pump and HERCULES trial at the Glaucoma 360 meeting.

John Berdahl, MD, practicing in Sioux Falls, South Dakota discussed the FYXS Ocular Pressure Adjusting Pump during the recent Glaucoma 360 meeting. This is the first non-surgical, non-drug treatment for glaucoma approved by the FDA in June 2024. The pump consists of 2 ocular chambers that attach to a negative pressure pump. When worn, the negative pressure draws some of the weight off the eye, causing the intraocular pressure (IOP) to decrease. Berdahl explains this using a simple analogy - if you press on the eye, the pressure increases, and when you release the pressure, it decreases.

Berdahl describes the HERCULES trial, which looked at 186 patients with normal tension glaucoma. The study found that 100% of patients experienced IOP lowering while wearing the pump, with 97% having more than a 20% reduction and an average 39% decrease from 20.2 mmHg to 12.2 mmHg. The safety profile was good, with only 17% experiencing some eyelid puffiness. Berdahl suggests the pump will be useful for patients with IOP less than 21 mmHg who have tried other therapies like eye drops, SLT or MIGS, but need additional IOP lowering before considering more invasive glaucoma surgery. He sees this as a significant innovation, marking a new category in glaucoma treatment after previous advancements in imaging, MIGS, and drug delivery.

Finally, Berdahl discusses the collaboration between optometry and ophthalmology in his rural state, where patients often travel long distances for care. He works closely with optometrists who manage the day-to-day clinic, while he is involved in surgical decisions and complex cases. This allows them to provide the most effective and efficient care for their patients.

Recent Videos
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Shan Lin, MD, and John Berdahl, MD, share their perspectives as ophthalmologists regarding the importance of comanagement.
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
© 2025 MJH Life Sciences

All rights reserved.